Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693692 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TD-9855 to Treat Fibromyalgia
A Phase 2 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 392
- Enrollment target
NCT01693692: Completed Phase 2 study, sponsored by Theravance Biopharma.
NCT01693692 is a Phase 2 study that has completed, run by Theravance Biopharma. The registered enrollment target is 392 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (195% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01693692, a Phase 2 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 392 participants
- Enrollment target
Study Summary
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Primary Outcome
Pain NRS score is based on an 11-point scale where 0 represents no pain and 10 represents the worst possible pain.
Interventions
- DRUG Placebo
- DRUG TD-9855 Group 1
- DRUG TD-9855 Group 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT01693692 record still lists
NCT01693692 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (195% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01693692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01693692 about?
NCT01693692 is a clinical study titled "Phase 2 Study of TD-9855 to Treat Fibromyalgia". The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
What is the current status of trial NCT01693692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 392 participants. The study started on 2012-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01693692?
The interventions under investigation include: Placebo (DRUG), TD-9855 Group 1 (DRUG), TD-9855 Group 2 (DRUG).
Who is sponsoring clinical trial NCT01693692?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01693692's enrollment target sits among peer trials
392 105th of 2000 higher than 1,895 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia